ACEI/ARB therapy for IgA nephropathy: A meta analysis of randomised controlled trials

International Journal of Clinical Practice

Volumn 63, Issue 6, 2009, Pages 880-888

  Cheng, J ^a,b   Zhang, W ^b   Zhang, X H ^a   He, Q ^a   Tao, X J ^b   Chen, J H ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b HANGZHOU RED CROSS HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; BENAZEPRIL; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FOSINOPRIL; LOSARTAN; NADOLOL; NIFEDIPINE; PLACEBO; RAMIPRIL; TEMOCAPRIL; TRANDOLAPRIL; VALSARTAN; CREATININE;

ARTICLE; CLINICAL TRIAL; COCHRANE LIBRARY; CONTROLLED CLINICAL TRIAL; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; EMBASE; GLOMERULUS FILTRATION RATE; HUMAN; IMMUNOGLOBULIN A NEPHROPATHY; KIDNEY FUNCTION; MEDLINE; META ANALYSIS; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE; BLOOD PRESSURE; DRUG EFFECTS; GLOMERULONEPHRITIS, IGA; METABOLISM; PATHOPHYSIOLOGY; PUBLISHING; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BLOOD PRESSURE; CREATININE; GLOMERULONEPHRITIS, IGA; HUMANS; PROTEINURIA; PUBLICATION BIAS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 65649143250     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2009.02038.x     Document Type: Article

References (42)

1. Berger J, Hinglais N. Les depots intercapillaires d'IgA-IgG. J Urol Nephrol 1968 74 : 694 5.
2. D'amico G. The commonest glomerulonephritis in the world: IgA nephropathy. Q J Med 1987 245 : 709 27.
3. Julian BA, Waldo FB, Rifai A, Mestecky J. IgA nephropathy, the most common glomerulonephritis worldwide: a neglected disease in the United States? Am J Med 1988 84 : 129 32.
4. Levy M, Berger J. Worldwide perspective of IgA nephropathy. Am J Kidney Dis 1988 12 : 340 7.
5. Schena FP. Immunoglobulin A nephropathy with mild renal lesions: a call in the forest for the physicians and nephrologists.Am. J Med 2001 110 : 499 500.
6. Rostoker G, Desvaux-Belghiti D, Pilatte Y et al. Immunomodulation with low-dose immunoglobulins for moderate IgAN and Henoch-Schonlein purpura. Preliminary results of a prospective uncontrolled trial. Nephron 1995 69 : 327 34.
7. Samuels JA, Strippoli GF, Craig JC et al. Immunosuppressive agents for treating IgA nephropathy. Cochrane Database Syst Rev 2003 4 : CD003965.
8. Barratt J, Feehally J. IgA nephropathy. J Am Soc Nephrol 2005 16 : 2088 97.
9. Floege J, Eitner F. Present and future therapy options in IgA nephropathy. J Nephrol 2005 18 : 354 61.
10. Maschio G, Alberti D, Janin G et al. Effect of the angiotensinconverting- enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med 1996 334 : 939 45.
11. The GISEN Group. Randomised placebo-controlled trial of effect of ramipril on declining in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 1997 349 : 1857 63.
12. Lewis EJ, Hunsicker L, Bain RP et al. The effect of angiotensin- converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993 329 : 1456 62.
13. Juni P, Altman DG, Egger M. Systematic reviews in health care: assessing the quality of controlled clinical trials. BMJ 2001 323 : 42 6.
14. Hollis S, Campbell F. What is meant by intention to treat analysis? Survey of published randomised controlled trials. BMJ 1999 319 : 670 4.
15. Schulz KF, Chalmers I, Hayes RJ et al. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995 273 : 408 12.
16. Jadad AR, Moore RA, Carroll D et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996 17 : 1 12.
17. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959 22 : 719 48.
18. Fleiss JL. Analysis of data from multiclinic trials. Control Clin Trials 1986 7 : 267 75.
19. Dersimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986 7 : 177 88.
20. Hou FF, Xie D, Zhang X et al. Renoprotection of Optimal Antiproteinuric Doses (ROAD) Study: a randomized controlled study of benazepril and losartan in chronic renal insufficiency. J Am Soc Nephrol 2007 18 : 1889 98.
21. Nakao N, Yoshimura A, Morita H et al. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 2003 361 : 117 24.
22. Ruggenenti P, Perna A, Gherardi G. Chronic proteinuric nephropathies: outcomes and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury. Am J Kidney Dis 2000 35 : 1155 65.
23. Bannister KM, Weaver A, Clarkson AR et al. Effect of angiotensin- converting enzyme and calcium channel inhibition on progression of IgA nephropathy. Contrib Nephrol 1995 111 : 184 92. discussion 192-3.
24. Cheng IKP, Fang GX, Wong MC et al. A randomized prospective comparison of nadolol, captopril with or without ticlopidine on disease progression in IgA nephropathy. Nephrology 1998 4 : 19 26.
25. Park HC, Xu ZG, Choi S et al. Effect of losartan and amlodipine on proteinuria and transforming growth factor-beta1 in patients with IgA nephropathy. Nephrol Dial Transplant 2003 18 : 1115 21.
26. Kanno Y, Okada H, Yamaji Y et al. Angiotensin-converting-enzyme inhibitors slow renal decline in IgA nephropathy, independent of tubulointerstitial fibrosis at presentation. QJM 2005 98 : 199 203.
27. Maschio G, Cagnoli L, Claroni F et al. ACE inhibition reduces proteinuria in normotensive patients with IgA nephropathy: a multicentre, randomized, placebo-controlled study. Nephrol Dial Transplant 1994 9 : 265 9.
28. Woo KT, Lau YK, Wong KS, Chiang GS. ACEI-ATRA therapy decreases proteinuria by improving glomerular permselectivity in IgA nephritis. Kidney Int 2000 58 : 2485 91.
29. Praga M, Gutiérrez E, González E et al. Treatment of IgAN with ACE inhibitors: a randomized and controlled trial. J Am Soc Nephrol 2003 14 : 1578 83.
30. Li PK, Leung CB, Chow KM et al. Hong Kong study using valsartan in IgAN(HKVIN): a double-blind,randomized, placebo-controlled study. Am J Kidney Dis 2006 47 : 751 60.
31. Woo KT, Lau YK, Zhao Y et al. Disease progression, response to ACEI-ATRA therapy and influence of ACE gene in IgA nephritis. Cell Mol Immunol 2007 4 : 227 32.
32. Coppo R, Peruzzi L, Amore A et al. IgACE: a placebo-controlled, randomized trial of angiotensin-converting enzyme inhibitors in children and young people with IgAN and moderate proteinuria. J Am Soc Nephrol 2007 18 : 1880 8. Epub 2007 May 18.
33. Nolin L, Courteau M. Management of IgA nephropathy: evidence-based recommendations. Kidney Int 1999 70 (Suppl. S56 62.
34. Strippoli GF, Manno C, Schena FP. An "evidence-based" survey of therapeutic options for IgA nephropathy: assessment and criticism. Am J Kidney Dis 2003 41 : 1129 39.
35. Samuels JA, Strippoli GF, Craig JC et al. Immunosuppressive treatments for immunoglobulin A nephropathy: a meta-analysis of randomized controlled trials. Nephrology (Carlton) 2004 9 : 177 85.
36. Kawamura T. Treatment of IgA nephropathy: corticosteroids, tonsillectomy, and mycophenolate mofetil. Contrib Nephrol 2007 157 : 37 43.
37. Navaneethan SD, Viswanathan G, Strippoli GF. Meta-analysis of mycophenolate mofetil in IgA nephropathy. Nephrology (Carlton) 2008 13 : 90.
38. Dillon JJ. Fish oil therapy for IgA nephropathy: efficacy and interstudy variability. J Am Soc Nephrol 1997 8 : 1739 44.
39. Taji Y, Kuwahara T, Shikata S et al. Meta-analysis of antiplatelet therapy for IgA nephropathy. Clin Exp Nephrol. 2006 10 : 268 73. Epub 2006 Dec 20.
40. Kunz R, Friedrich C, Wolbers M et al. Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann Intern Med 2008 148 : 30 48. Epub 2007 Nov 5.
41. Hebert LA, Wilmer WA, Falkenhain ME et al. Renoprotection: One or many therapies? Kidney Int 2001 59 : 1211 26.
42. Wilmer WA, Rovin BH, Herbert CJ et al. Management of glomerular proteinuria: a commentary. J Am Soc Nephrol 2003 14 : 3217 32.